In this report, we emphasize the importance of public monographs with reference materials, coupled with careful process and change control and attention to GMPs, as a means of advancing access to good quality, safe, and effective medicines, with emphasis on available and incoming biologic medicines. With adequate control of articles covered by a monograph, these public standards can form the basis for a global public quality platform that covers reference products, non-interchangeable reference products, biosimilars, and interchangeable biosimilars. Working collaboratively with all stakeholders, new approaches allow these public standards to emerge nationally and globally in a timely way. Yet, there are increasing limitations in the availability of public standards for biologic medicines, which may reverse many decades of progress. Solutions are considered in this report. Tablica mendeleeva po himii. INTRODUCTION Biologic medicines are an increasing component of the therapeutic armamentarium of practitioners, with a long and distinguished history of value to patients/consumers.

The increase in the medicinal value of biologics is expected to expand with improved understanding of human and animal biology and rising capability of manufacturers to make safe, effective, and good quality biologics through recombinant technology. Equally important, global, regional, and national approaches to first-entry reference products, other reference products with the same active moiety but without comparison to the first (referred in this article as a non-interchangeable reference products), biosimilars, and interchangeable biosimilars, with the understanding that a global ingredient and product quality platform can be developed that is suitable for all four categories (Fig. ). We argue that a key component of this platform is a public monograph with allied reference materials that, for potency, are traceable to a World Health Organization (WHO) biological reference material (BRM), denoted as a WHO international standard or reference reagent (). This report follows a larger paper published by the US Pharmacopeial Convention (USP) that considered primary and secondary standards, together with monographs, for food and drug articles (). Four categories are emerging globally for a biologic product: (1) reference product, (2) one or more non-interchangeable reference products, (3) one or more biosimilar products to each reference product, and (4) interchangeable biosimilar reference products (USA only). All can be linked via common unitage traceable to an available WHO biological reference material with specified unitage.

Pending Monographs; Purchase USP–NF. USP–NF Spanish Edition; USP–NF Archive Products. FILGRASTIM - 2013-10-01. Monograph Title. Errata Identifier. Line 7 of Preparation of cells for analysis: Change Column 1 is filled with 50 L of Medium B. To: Column 1 is filled with 50 µL of Medium.

For categories 1 and 2, clinical trial designs might be based either on demonstrating a difference (two-sided) or non-inferiority (one-sided). For categories 3 and 4, designs are based on demonstrating similarity with criteria for population or individual equivalence.